Rhapsido 25 MG Oral Tablet
- RxCUI
- 2724398
- RxNorm name
- Rhapsido 25 MG Oral Tablet
- Display name
- Rhapsido 25 MG Oral Tablet
- Full name
- Rhapsido 25 MG Oral Tablet
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:25
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| RHAPSIDO | REMIBRUTINIB | Novartis Pharmaceuticals Corporation | e5e89bff-6ced-4165-acc5-fb13136b3a3d | 2026-10-06 | Warnings, Adverse reactions | 2724398 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| e5e89bff-6ced-4165-acc5-fb13136b3a3d | Rhapsido 25 MG Oral Tablet [PSN] · remibrutinib 25 MG Oral Tablet [Rhapsido] [SBD] · Rhapsido 25 MG Oral Tablet [SY] | 3 | 2 | These highlights do not include all the information needed to use RHAPSIDO safely and effectively. See full prescribing information for RHAPSIDO. RHAPSIDO ® (remibrutinib) tablets, for oral use Initial U.S. Approval: 2025 | 20260323 |